Clobetasone is a corticosteroid used in dermatology, for treating such skin inflammation as seen in eczema, psoriasis and other forms of dermatitis, and ophthalmology. It is typically formulated as clobetasone butyrate for topical use and acts via high affinity binding to glucocorticoid receptors to suppress inflammatory gene transcription, reduce proinflammatory cytokine release, and induce vasoconstriction and antiproliferative effects in the epidermis. Topical clobetasone butyrate has shown minimal suppression of the hypothalamic–pituitar + some more technical info: systemic absorption from intact skin is low under recommended use, plasma concentrations after topical application are generally below quantification in pharmacokinetic assays, and systemic half-life after inadvertent systemic exposure is short; local adverse effects such as skin atrophy, telangiectasia, and folliculitis remain the primary safety considerations and risk increases with potency, duration of use, occlusion, or broken skin.
Parent: Clobetasone
Parent: Clobetasone
Parent: Clobetasone
Parent: Clobetasone
Parent: Clobetasone
Parent: CLOBETASONE
Parent: Clobetasone
Parent: Clobetasone Butyrate /Clobetasone
Manufacturing and stability monitoring typically targets a small set of related compounds and degradation products with defined acceptance criteria measured by validated HPLC or LC-MS methods. Common related compounds include the de-esterified alcohol (clobetasone alcohol), 21-hydroxy and 17-hydroxy positional/oxidation products, the 16-epimer, an 11-keto oxidation product, and potential 9-defluoro or double-bond migration impurities; typical specification ranges used in dossiers and monographs are individual identified impurities not exceeding 0.2 to 0.5% by area percent and total impurities not exceeding 1.0% by area percent, with any unspecified or potentially genotoxic impurity limited to trace levels consistent with ICH M7 guidance (generally <0.05% or per permitted daily exposure calculations). Stability protocols also monitor solvent-related residues and water content and set tighter limits for highly active or toxic degradation species, with corrective controls in the synthetic route and formulation to minimize hydrolysis and oxidation pathways.
Clobetasone cream is used topically to reduce inflammation, itching, and redness in corticosteroid-responsive dermatoses such as mild to moderate eczema, contact dermatitis, seborrheic dermatitis, and some inflammatory scalp conditions; use should follow prescribing guidance on duration and site to limit local and systemic adverse effects.
Clobetasone butyrate is marketed under several brand names that vary by country, commonly including names such as Eumovate and Clobavate; exact brand availability depends on regional regulatory approvals and manufacturers.
Clobetasone is generally classified as a mild topical corticosteroid with potency comparable to or slightly greater than low strength hydrocortisone preparations; relative clinical potency depends on concentration, formulation, vehicle, and the treated site, so direct comparisons should reference specific product strengths.
Clobavate S ointment is a commercial formulation of clobetasone intended for topical treatment of inflammatory dermatoses; product indications, vehicle characteristics, and any adjunct ingredients vary by manufacturer, so always consult the product label or local prescribing information for exact use recommendations.
